CSF1R and glioblastoma: In patients with recurrent glioblastoma treated with an oral CSF-1R inhibitor PLX3397, the percentage of non-classical monocytes (CD14loCD16+) declined after treatment but microglia in the tumor microenvironment were only modestly reduced (105).